-
EP4100405
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4100405
| EP4100405 - MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 11.11.2022 Database last updated on 06.11.2024 | |
| Former | The international publication has been made Status updated on 13.08.2021 | ||
| Former | unknown Status updated on 09.03.2021 | Most recent event Tooltip | 03.01.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543 / US | [2022/50] | Inventor(s) | 01 /
NGU, Khehyong c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, New Jersey 08543 / US | 02 /
ANNUNZIATO, Christopher 2631 Town Court North Lawrence, New Jersey 08648 / US | 03 /
DUNCIA, John V. c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, New Jersey 08543 / US | 04 /
GARDNER, Daniel S. c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, New Jersey 08543 / US | [2022/50] | Representative(s) | Dehns 10 Old Bailey London EC4M 7NG / GB | [N/P] |
| Former [2022/50] | Dehns St. Bride's House 10 Salisbury Square London EC4Y 8JD / GB | Application number, filing date | 21708867.3 | 05.02.2021 | [2022/50] | WO2021US16698 | Priority number, date | US202062970832P | 06.02.2020 Original published format: US 202062970832 P | [2022/50] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021158840 | Date: | 12.08.2021 | Language: | EN | [2021/32] | Type: | A1 Application with search report | No.: | EP4100405 | Date: | 14.12.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 12.08.2021 takes the place of the publication of the European patent application. | [2022/50] | Search report(s) | International search report - published on: | EP | 12.08.2021 | Classification | IPC: | C07D403/14, C07D487/04, C07D487/08, A61K31/437, A61K31/439, A61K31/445, A61P19/00 | [2022/50] | CPC: |
C07D403/14 (EP);
C07D487/08 (EP,KR);
C07D471/22 (KR,US);
A61K31/439 (KR);
A61K45/06 (US);
A61P1/00 (KR);
A61P19/02 (KR);
A61P29/00 (KR);
A61P35/00 (KR);
A61P37/00 (KR);
C07D487/04 (EP);
C07D487/22 (KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/50] | Title | German: | MAKROCYCLISCHE PAD4-INHIBITOREN ALS IMMUNSUPPRESSIVUM | [2022/50] | English: | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | [2022/50] | French: | INHIBITEURS MACROCYCLIQUES DE PAD4 UTILES EN TANT QU'IMMUNOSUPPRESSEURS | [2022/50] | Entry into regional phase | 02.09.2022 | National basic fee paid | 02.09.2022 | Designation fee(s) paid | 02.09.2022 | Examination fee paid | Examination procedure | 02.09.2022 | Examination requested [2022/50] | 02.09.2022 | Date on which the examining division has become responsible | 23.03.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 30.12.2022 | Renewal fee patent year 03 | 03.01.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2014015905 (GLAXO GROUP LTD [GB], et al) [A] 1-22* example -; claim - *; | [A]WO2018022897 (PADLOCK THERAPEUTICS INC [US]) [A] 1-22 * example -; claim - * | by applicant | - JONES J.E. et al., Curr. Opin. Drug Discov. Devel., (20090000), vol. 12, no. 5, pages 616 - 627 | - WEGNER N. et al., Immunol. Rev., (20100000), vol. 233, no. 1, pages 34 - 54 | - KOCHI Y. et al., Ann. Rheum. Dis., (20110000), vol. 70, pages 512 - 515 | - NEELI I. et al., J. Immunol., (20080000), vol. 180, pages 1895 - 1902 | - LI P. et al., J. Exp. Med., (20100000), vol. 207, no. 9, pages 1853 - 1862 | - KESSENBROCKK. et al., Nat. Med., (20090000), vol. 15, no. 6, pages 623 - 625 | - HAKKIM A. et al., Proc. Natl. Acad. Sci. USA, (20100000), vol. 107, no. 36, pages 15880 - 9818 | - VILLANUEVA E. et al., J. Immunol., (20110000), vol. 186, no. 7, pages 4396 - 4404 | - SAVCHENKO A. et al., Pathol. Int., (20110000), vol. 61, no. 5, pages 290 - 7 | - DWORSKI R. et al., J. Allergy Clin. Immunol., (20110000), vol. 127, no. 5, pages 1260 - 6 | - VITKOV L. et al., Ultrastructural Pathol., (20100000), vol. 34, no. 1, pages 25 - 30 | - CLARK S.R. et al., Nat. Med., (20070000), vol. 13, no. 4, pages 463 - 9 | - BRINKMANN V et al., Science, (20040000), vol. 303, pages 1532 - 5 | - CHUMANEVICH A.A. et al., Am. J. Physiol. Gastrointest. Liver Physiol., (20110000), vol. 300, no. 6, pages G929 - G938 | - LANGE S. et al., Dev. Biol., (20110000), vol. 355, no. 2, pages 205 - 14 | - SLACK.J.L. et al., Cell. Mol. Life Sci., (20110000), vol. 68, no. 4, pages 709 - 720 | - CHANGX. et al., BMC Cancer, (20090000), vol. 9, page 40 | - LI P. et al., Mol. Cell Biol., (20080000), vol. 28, no. 15, pages 4745 - 4758 | - The Peptides: Analysis, Synthesis, Biology, Academic Press, (19810000), vol. 3 | - Methods in Enzymology, Academic Press, (19850000), vol. 112, pages 309 - 396 | - "Design and Application of Prodrugs", BUNDGAARD, H. et al., A Textbook of Drug Design and Development, Harwood Academic Publishers, (19910000), pages 113 - 191 | - BUNDGAARD, H., Adv. Drug Deliv. Rev., (19920000), vol. 8, pages 1 - 38 | - BUNDGAARD, H. et al., J. Pharm. Sci., (19880000), vol. 77, page 285 | - KAKEYA, N. et al., Chem. Pharm. Bull., (19840000), vol. 32, page 692 | - Prodrugs and Targeted Delivery (Methods and Principles in Medicinal Chemistry), Wiley-VCH, (20110000), vol. 47 |